114 related articles for article (PubMed ID: 10197410)
1. Synthesis and hypolipidaemic evaluation of a series of alpha-asarone analogues related to clofibrate in mice.
Labarrios F; Garduño L; Vidal MR; Garcia R; Salazar M; Martinez E; Diaz F; Chamorro G; Tamariz J
J Pharm Pharmacol; 1999 Jan; 51(1):1-7. PubMed ID: 10197410
[TBL] [Abstract][Full Text] [Related]
2. Hypolipidaemic and antiplatelet activity of phenoxyacetic acid derivatives related to alpha-asarone.
Pérez-Pastén R; García RV; Garduño L; Reyes E; Labarrios F; Tamariz J; Chamorro G
J Pharm Pharmacol; 2006 Oct; 58(10):1343-9. PubMed ID: 17034657
[TBL] [Abstract][Full Text] [Related]
3. Effect of alpha-asarone and a derivative on lipids, bile flow and Na+/K+-ATPase in ethinyl estradiol-induced cholestasis in the rat.
Garduño-Siciliano L; Labarrios F; Tamariz J; Moreno MG; Chamorro G; Muriel P
Fundam Clin Pharmacol; 2007 Feb; 21(1):81-8. PubMed ID: 17227448
[TBL] [Abstract][Full Text] [Related]
4. Hypolipemic activity of clofibrate-related compounds.
Metz G; Specker M
Arzneimittelforschung; 1975 Nov; 25(11):1686-92. PubMed ID: 1243074
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and hypolipidemic and antiplatelet activities of alpha-asarone isomers in humans (in vitro), mice (in vivo), and rats (in vivo).
Poplawski J; Lozowicka B; Dubis AT; Lachowska B; Witkowski S; Siluk D; Petrusewicz J; Kaliszan R; Cybulski J; Strzałkowska M; Chilmonczyk Z
J Med Chem; 2000 Oct; 43(20):3671-6. PubMed ID: 11020281
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and hypolipidemic activity of modified side chain alpha-asarone homologues.
Cruz A; Garduño L; Salazar M; Martínez E; Jiménez-Vázquez HA; Díaz F; Chamorro G; Tamariz J
Arzneimittelforschung; 2001; 51(7):535-44. PubMed ID: 11505784
[TBL] [Abstract][Full Text] [Related]
7. Effects of S-8527 (1,1-bis(4'-(1'-carboxy-1'-methylpropoxy)phenyl) cyclohexane), a new hypolipidemic compound, on cholesterol and lipoprotein metabolism in rats.
Suzuki K
Biochem Pharmacol; 1976 Feb; 25(3):325-8. PubMed ID: 1267828
[No Abstract] [Full Text] [Related]
8. Synthesis and hypolipidemic activity of 2-substituted isobutyric acid derivatives.
Morishita S; Saito T; Hirai Y; Shoji M; Mishima Y; Kawakami M
J Med Chem; 1988 Jun; 31(6):1205-9. PubMed ID: 3163736
[TBL] [Abstract][Full Text] [Related]
9. The lipid-lowering profile in rodents. AZ-1355, a new dibenzoxazepine derivative.
Wada S; Koizumi M; Sasahara K; Neichi T; Nakakimura H; Onoda F; Hata SI
Atherosclerosis; 1981; 40(3-4):263-71. PubMed ID: 7332605
[TBL] [Abstract][Full Text] [Related]
10. Effect of BM 15.075 on lipoprotein concentrations in different types of hyperlipoproteinaemia.
Olsson AG; Rössner S; Walldius G; Carlson LA; Lang PD
Atherosclerosis; 1977 Jul; 27(3):279-87. PubMed ID: 901625
[TBL] [Abstract][Full Text] [Related]
11. Effect of KC-9432, a new hypolipidemic compound, on high density lipoprotein cholesterol in rats.
Seri K; Sato R; Hamazaki Y; Yamamoto T; Ishiyama N
Atherosclerosis; 1980 Sep; 37(1):97-102. PubMed ID: 6893550
[TBL] [Abstract][Full Text] [Related]
12. [Hypolipidemic activity of substances structurally close to penphenone in rats and mice].
Polikarpova LI; Reznik SE; Ryzhenkov VV; Khechinashvili GG; Petrova LA
Vopr Med Khim; 1978; 24(6):835-9. PubMed ID: 216145
[TBL] [Abstract][Full Text] [Related]
13. Fibric acids: effects on lipids and lipoprotein metabolism.
Grundy SM; Vega GL
Am J Med; 1987 Nov; 83(5B):9-20. PubMed ID: 3318457
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of benzodioxane, chroman and dihydrobenzofuran analogs of clofibrate in a Triton hyperlipemic rat model.
Newman HA; Heilman WP; Witiak DT
Lipids; 1973 Jul; 8(7):378-84. PubMed ID: 4724016
[No Abstract] [Full Text] [Related]
15. 2,4,5-trimethoxycinnamic acid: the major metabolite of alpha-asarone, retains most of the pharmacological properties of alpha-asarone.
Antunez-Solis J; Hernández-Derramadero F; Aquino-Vega M; Ibarra-Ramírez S; Rodríguez-Páez L; Baeza I; Wong C
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):903-9. PubMed ID: 18686138
[TBL] [Abstract][Full Text] [Related]
16. Studies of hypolipidemic agents. 1. Synthesis and hypolipidemic activities of alkoxycinnamic acid derivatives.
Watanabe T; Hayashi K; Yoshimatsu S; Sakai K; Takeyama S; Takashima K
J Med Chem; 1980 Jan; 23(1):50-9. PubMed ID: 7359513
[TBL] [Abstract][Full Text] [Related]
17. Hypolipidemic activity of indan-1,3-dione derivatives in rodents.
Murthy AR; Wyrick SD; Hall IH
J Med Chem; 1985 Nov; 28(11):1591-6. PubMed ID: 4067989
[TBL] [Abstract][Full Text] [Related]
18. Effect of clofibrate on lipoprotein metabolism in hyperlipidemic rats.
Segal P; Roheim PS; Eder HA
J Clin Invest; 1972 Jul; 51(7):1632-8. PubMed ID: 4338117
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological profile of BR-931, a new hypolipidemic agent that increases high-density lipoproteins.
Sirtori CR; Gomarasca P; D'Atri G; Cerutti S; Tronconi G; Scolastico C
Atherosclerosis; 1978 May; 30(1):45-56. PubMed ID: 209796
[TBL] [Abstract][Full Text] [Related]
20. The mechanism underlying the hypolipemic effect of perfluorooctanoic acid (PFOA), perfluorooctane sulphonic acid (PFOSA) and clofibric acid.
Haughom B; Spydevold O
Biochim Biophys Acta; 1992 Sep; 1128(1):65-72. PubMed ID: 1327145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
